The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Drug resistance in metastatic castration-resistant prostate cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“Furthermore, most men treated with docetaxel experienced progression of their disease within 1 year from the start of treatment”
BackgroundSelf-citationMultidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292 · cited 1×
“MDV3100 is a second-generation antiandrogen diarylthiohydantoin that acts as a potent antagonist of the AR in CRPC cells, including those with overexpressed or mutated AR”
BackgroundMolecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222 · cited 1×
“Increased interstitial fluid pressure due to the leaky and disorganized vasculature, coupled with absent or poorly formed lymphatic drainage, also impairs drug delivery in tumors”
BackgroundDrug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“journal CME activity: (1) review the learning objectives and author”
BackgroundSelf-citationDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Self-citationMicrotubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Integrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 819
Koivisto, P. A., Kononen, J., Palmberg, C., Tammela, T. L. J., HYYTINEN, E.-R., Isola, J. J., Trapman, J., Cleutjens, K. B. J. M., Noordzij, M. A., Visakorpi, T., et al. (1997) · PubMed · Cited by 728
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674 · cited 1×
“disclosures; (2) study the education content; (3) take the post-test”
BackgroundAndrogen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
Osteoblasts in prostate cancer metastasis to bone
Logothetis, C. J., & Lin, S.-H. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1528 · Cited by 614
Bcl2 is the guardian of microtubule integrity.
Haldar, S., Basu, A., & Croce, C. M. (1997) · PubMed · Cited by 599
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577 · cited 1×
“Despite the possible existence of truly 'androgen-independent' clones of cancer cells in CRPC, immunohistological and gene-expression studies have shown that the majority of prostatic cancer cells remain dependent on AR-associated signaling, despite the maintenance of castrate levels of testosterone in the blood durin…”
BackgroundRaffo, A. J., Perlman, H., Chen, M., Day, M. L., Streitman, J., & Buttyan, R. (1995) · PubMed · Cited by 542
(2001) · PubMed · Cited by 500
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499
Self-citationNormal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
Xu, J., Wu, R.-C., & O'Malley, B. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2695 · Cited by 488
Tremblay, A., Tremblay, G. B., Labrie, F., & Giguère, V. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80479-7 · Cited by 464
Microtubule-targeted anticancer agents and apoptosis
Bhalla, K. N. (2003) · Oncogene · doi:10.1038/sj.onc.1207233 · Cited by 461
Danila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., Taplin, M.-E., Bubley, G. J., Kheoh, T., Haqq, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9259 · Cited by 410
Tu, S.-M., Millikan, R. E., Mengistu, B., Delpassand, E. S., Amato, R. J., Pagliaro, L. C., Daliani, D., Papandreou, C. N., Smith, T. L., Kim, J., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03639-4 · Cited by 396
Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer
Dahut, W. L., Gulley, J. L., Arlen, P. M., Liu, Y., Fedenko, K. M., Steinberg, S. M., Wright, J. J., Parnes, H., Chen, C. C., Jones, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.074 · Cited by 351
Prostate Cancer Stem Cells: A New Target for Therapy
Maitland, N. J., & Collins, A. T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1472 · Cited by 350
Sternberg, C. N., Petrylak, D. P., Sartor, O., Witjes, J. A., Demkow, T., Ferrero, J.-M., Eymard, J.-C., Falcon, S., Calabrò, F., James, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1228 · Cited by 340
Carducci, M. A., Saad, F., Abrahamsson, P., Dearnaley, D. P., Schulman, C. C., North, S. A., Sleep, D. J., Isaacson, J. D., Nelson, J. B., & for the Atrasentan Phase III Study Group Institutions. (2007) · Cancer · doi:10.1002/cncr.22996 · Cited by 294
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286 · cited 1×
“In addition, resistance can be caused by the activation of other oncogenic survival pathways that promote drug resistance by activation of the AR and/or by independent mechanisms”
BackgroundAcquired multicellular-mediated resistance to alkylating agents in cancer.
Kobayashi, H., Man, S., Graham, C. H., Kapitain, S. J., Teicher, B. A., & Kerbel, R. S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3294 · Cited by 278
Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
Sève, P., & Dumontet, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70029-9 · Cited by 274
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.11.006 · Cited by 242
Survivin mediates resistance to antiandrogen therapy in prostate cancer
Zhang, M., Latham, D. E., Delaney, M. A., & Chakravarti, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208490 · Cited by 223
Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth
Zhang, J., Lu, Y., & Pienta, K. J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq044 · Cited by 216
Canil, C. M., Moore, M. J., Winquist, E., Baetz, T., Pollak, M., Chi, K. N., Berry, S., Ernst, D. S., Douglas, L., Brundage, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.129 · Cited by 210
Tamura, K., Furihata, M., Tsunoda, T., Ashida, S., Takata, R., Obara, W., Yoshioka, H., Daigo, Y., Nasu, Y., Kumon, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4040 · Cited by 206
Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., Qi, M., Bandekar, R., Vermeulen, J. T., Cornfeld, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.014 · Cited by 197
The role of Src in prostate cancer
Fizazi, K. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm086 · Cited by 183
The role of androgen receptor mutations in prostate cancer progression.
Brooke, G., & Bevan, C. (2009) · Current Genomics · doi:10.2174/138920209787581307 · Cited by 181
The role of MAPK pathways in the action of chemotherapeutic drugs
Boldt, S. (2002) · Carcinogenesis · doi:10.1093/carcin/23.11.1831 · Cited by 175
Fizazi, K., Beuzeboc, P., Lumbroso, J., Haddad, V., Massard, C., Gross-Goupil, M., Di Palma, M., Escudier, B., Theodore, C., Loriot, Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9811 · Cited by 173
Limited Tissue Penetration of Taxanes: A Mechanism for Resistance in Solid Tumors
Kyle, A. H., Huxham, L. A., Yeoman, D. M., & Minchinton, A. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1941 · Cited by 172
Crosstalk between the Androgen Receptor and β-Catenin in Castrate-Resistant Prostate Cancer
Wang, G., Wang, J., & Sadar, M. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1718 · Cited by 168
Domingo-Domenech, J., Oliva, C., Rovira, A., Codony-Servat, J., Bosch, M., Filella, X., Montagut, C., Tapia, M., Campás, C., Dang, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2767 · Cited by 166
Wu, L., Birle, D. C., & Tannock, I. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3137 · Cited by 164
Self-citationMumenthaler, S. M., Ng, P. Y. B., Hodge, A., Bearss, D. J., Berk, G., Kanekal, S., Redkar, S., Taverna, P., Agus, D. B., & Jain, A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0293 · Cited by 154
Ning, Y. M., Gulley, J. L., Arlen, P. M., Woo, S., Steinberg, S. M., Wright, J. J., Parnes, H. L., Trepel, J. B., Lee, M.-J., Kim, Y. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4524 · Cited by 153
Do β-tubulin mutations have a role in resistance to chemotherapy?
Berrieman, H. K., Lind, M., & Cawkwell, L. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01411-1 · Cited by 153
Zelivianski, S., Spellman, M., Kellerman, M., Kakitelashvilli, V., Zhou, X., Lugo, E., Lee, M., Taylor, R., Davis, T. L., Hauke, R. J., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11413 · Cited by 151
Bono, J. S. D., Joaquim Bellmunt, B., Attard, G., Droz, J. P., Miller, K., Fléchon, A., Sternberg, C. N., Parker, C. C., Zugmaier, G., Hersberger-Gimenez, V., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0888 · Cited by 151
Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
Zoubeidi, A., Chi, K., & Gleave, M. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2917 · Cited by 142
Kelly, W. K., Halabi, S., Carducci, M. A., George, D. J., Mahoney, J. F., Stadler, W. M., Morris, M. J., Kantoff, P. W., Monk, J. P., Small, E. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.18_suppl.lba4511 · Cited by 141
Neuroendocrine differentiation in the progression of prostate cancer
Komiya, A., Suzuki, H., Imamoto, T., Kamiya, N., Nihei, N., Naya, Y., Ichikawa, T., & Fuse, H. (2008) · International Journal of Urology · doi:10.1111/j.1442-2042.2008.02175.x · Cited by 140
Sonpavde, G., Periman, P., Bernold, D. M., Weckstein, D. J., Fleming, M. T., Galsky, M. D., Berry, W. R., Zhan, F., Boehm, K. A., Asmar, L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp323 · Cited by 137
Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
Mendiratta, P., Mostaghel, E. A., Guinney, J., Tewari, A. K., Porrello, A., Barry, W. T., Nelson, P. S., & Febbo, P. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2882 · Cited by 135
Sternberg, C. N., Dumez, H., Poppel, H. V., Skoneczna, I., Sella, A., Daugaard, G., Gil, T., Graham, J., Carpentier, P., Calabrò, F., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn784 · Cited by 125
Pchejetski, D., Doumerc, N., Golzio, M., Naymark, M., Teissié, J., Kohama, T., Waxman, J., Malavaud, B. A., & Cuvillier, O. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2322 · Cited by 120
Qian, D. Z., Rademacher, B. L. S., Pittsenbarger, J., Huang, C., Myrthue, A., Higano, C. S., Garzotto, M. G., Nelson, P. S., & Beer, T. M. (2009) · The Prostate · doi:10.1002/pros.21077 · Cited by 114
Exploring the Origins of the Normal Prostate and Prostate Cancer Stem Cell
Kasper, S. (2008) · Stem Cell Reviews and Reports · doi:10.1007/s12015-008-9033-1 · Cited by 108
Berthold, D., Pond, G. R., de Wit, R., Eisenberger, M. A., & Tannock, I. F. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn288 · Cited by 107
Self-citationBanerjee, S., Hussain, M., Wang, Z., Saliganan, A. D., Che, M., Bonfil, R. D., Cher, M. L., & Sarkar, F. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3879 · Cited by 94
Mimeault, M., Johansson, S. L., Venkatraman, G., Moore, E., Hénichart, J., Depreux, P., Lin, M., & Batra, S. K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0648 · Cited by 91
Machiels, J., Mazzeo, F., Clausse, M., Filleul, B., Marcelis, L., Honhon, B., D'Hondt, L. A., Dopchie, C., Verschaeve, V., Duck, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9524 · Cited by 90
Gross, M. E., Higano, C. S., Pantuck, A. J., Castellanos, O. O., Green, E., NGUYEN, K. N., & Agus, D. B. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-142 · Cited by 84
Early Androgen Deprivation for Prostate Cancer?
Eisenberger, M. A., & Walsh, P. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412409 · Cited by 74
Yang, C.-C., Lin, H.-P., Chen, C., Yang, Y.-T. C., Tseng, P., Rangnekar, V. M., & Chen, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301744200 · Cited by 72
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer
Gravis, G., Bladou, F., Salem, N., Gonçalvès, A., Esterni, B., Walz, J. C., Bagattini, S., Marcy, M., Brunelle, S., & Viens, P. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn174 · Cited by 65
Yamanaka, K., Rocchi, P., Miyake, H., Fazli, L., So, A., Zangemeister‐Wittke, U., & Gleave, M. E. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06147.x · Cited by 63
Alterations in γ-Actin and Tubulin-Targeted Drug Resistance in Childhood Leukemia
Verrills, N. M., Po’uha, S. T., Liu, M. L. M., Liaw, T. Y. E., Larsen, M. R., Ivery, M. T. G., Marshall, G. M., Gunning, P. W., & Kavallaris, M. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj372 · Cited by 63
Ryan, C. J., Efstathiou, E., Smith, M. R., Taplin, M. E., Bubley, G. J., Logothetis, C. J., Kheoh, T. S., Haqq, C., Molina, A., & Small, E. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.5046 · Cited by 24
Epothilones: tubulin polymerization as a novel target for prostate cancer therapy
Lee, J. J., & Kelly, W. K. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1281 · Cited by 22
Danila, D. C., Bono, J. S. D., Ryan, C. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.5048 · Cited by 18
Cited by
Antonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1341 · Cited by 618
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
Domingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.016 · Cited by 416
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Cai, M., Song, X.-L., Li, X.-A., Chen, M., Guo, J., Yang, D.-H., Chen, Z., & Zhao, S.-C. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100962 · Cited by 262
Bone metastasis in prostate cancer: emerging therapeutic strategies
Sturge, J., Caley, M. P., & Waxman, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.67 · Cited by 256
Metadata
- Authors
- Seruga, B., Ocana, A., & Tannock, I. F.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2010-09-21
- Volume
- 8
- Issue
- 1
- Pages
- 12-23
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2051410494
- Cited by
- 336
- References
- 86
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.